Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating waldenstrom's macroglobulinemia
AssigneesNereus Pharmaceuticals, Inc., Dana-Farber Cancer Institute, Inc.
InventorsIrene Ghobrial, Aldo Roccaro, Dharminder Chauhan, Kenneth Anderson, Michael A. Palladino
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.
Claims38
A method of treating Waldenstrom's Macroglobulinemia comprising administering to an animal a compound having the structure of Formula I, or a pharmaceutically acceptable salt or pro-drug ester thereof:
- wherein R1, R3, and R4 are separately selected from the group consisting of a hydrogen, a halogen, a mono-substituted, a poly-substituted or an unsubstituted variant of the following residues:
- saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, thio, sulfoxide, sulfone, sulfonate esters, thiocyano, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl;
- wherein m is equal to 1 or 2;
- wherein n is equal to 1 or 2;
- wherein each of E1, E2, E3 and E4 is a substituted or unsubstituted heteroatom;
- and
- wherein E5 is selected from the group consisting of OH, O, OR10, S, SR11, SO2R11, NH, NH2, NOH, NHOH, NR12, and NHOR13.
A method of treating Waldenstrom's Macroglobulinemia comprising administering to an animal a compound having the structure of Formula I-15, or a pharmaceutically acceptable salt or pro-drug ester thereof:
- wherein R8 is hydrogen, fluorine, chlorine, bromine or iodine.
A method of inhibiting the growth of a Waldenstrom's Macroglobulinemia cell comprising contacting the cell with a compound having the structure of Formula I, or a pharmaceutically acceptable salt or pro-drug ester thereof:
- wherein R1, R3, and R4 are separately selected from the group consisting of a hydrogen, a halogen, a mono-substituted, a poly-substituted or an unsubstituted variant of the following residues:
- saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, thio, sulfoxide, sulfone, sulfonate esters, thiocyano, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl;
- wherein m is equal to 1 or 2;
- wherein n is equal to 1 or 2;
- wherein each of E1, E2, E3 and E4 is a substituted or unsubstituted heteroatom;
- and
- wherein E5 is selected from the group consisting of OH, O, OR10, S, SR11, SO2R11, NH, NH2, NOH, NHOH, NR12, and NHOR13.
A method of inhibiting the growth of a Waldenstrom's Macroglobulinemia cell comprising contacting the cell with a compound having the structure of Formula I-15, or a pharmaceutically acceptable salt or pro-drug ester thereof:
- wherein R8 is hydrogen, fluorine, chlorine, bromine or iodine.
A method of inducing apoptosis of a Waldenstrom's Macroglobulinemia cell comprising contacting the cell with a compound having the structure of Formula I, and a pharmaceutically acceptable salt or pro-drug ester thereof:
- wherein R1, R3, and R4 are separately selected from the group consisting of a hydrogen, a halogen, a mono-substituted, a poly-substituted or an unsubstituted variant of the following residues:
- saturated C1-C24 alkyl, unsaturated C2-C24 alkenyl or C2-C24 alkynyl, acyl, acyloxy, alkyloxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, heteroaryl, arylalkoxy carbonyl, alkoxy carbonylacyl, amino, aminocarbonyl, aminocarboyloxy, nitro, azido, phenyl, cycloalkylacyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxy, cyano, thio, sulfoxide, sulfone, sulfonate esters, thiocyano, boronic acids and esters, and halogenated alkyl including polyhalogenated alkyl;
- wherein m is equal to 1 or 2;
- wherein n is equal to 1 or 2;
- wherein each of E1, E2, E3 and E4 is a substituted or unsubstituted heteroatom;
- and
- wherein E5 is selected from the group consisting of OH, O, OR10, S, SR11, SO2R11, NH, NH2, NOH, NHOH, NR12, and NHOR13;
A method of inducing apoptosis of a Waldenstrom's Macroglobulinemia cell comprising contacting the cell with a compound having the structure of Formula I-15 and a pharmaceutically acceptable salt or pro-drug ester thereof:
- wherein R8 is hydrogen, fluorine, chlorine, bromine or iodine.
Dependencies are inferred from the claim text.